7 research outputs found
Metacognitive Reflection and Insight Therapy (MERIT) with a Patient with Persistent Negative Symptoms
Metacognition comprises a spectrum of mental activities involving thinking about thinking. Metacognitive impairments may sustain and trigger negative symptoms in people with schizophrenia. Without complex ideas of the self and others, there may be less reason to pursue goal-directed activities and less ability to construct meaning in daily activities, leading to the experience of negative symptoms. As these symptoms tend to be nonresponsive to pharmacotherapy and other kinds of treatment metacognition might be a novel treatment target; improvement of metacognition might lead to improvements in negative symptoms. One therapy that seeks to promote metacognition is the Metacognitive Reflection and Insight Therapy (MERIT). In this study, a case is presented in which a first episode patient with severe negative symptoms is treated with MERIT. A case illustration and the eight core principles of MERIT are presented. Independent assessments of metacognition and negative symptoms before and after therapy show a significant increase of metacognition and decrease of negative symptoms over the course of 40 weeks
Practical Implications of Metacognitively Oriented Psychotherapy in Psychosis: Findings From a Pilot Study
In preparation for a multicenter randomized controlled trial, a pilot study was conducted investigating the feasibility and acceptance of a shortened version (12 vs. 40 sessions) of an individual metacognitive psychotherapy (Metacognitive Reflection and Insight Therapy [MERIT]). Twelve participants with a diagnosis of schizophrenia were offered 12 sessions of MERIT. Effect sizes were calculated for changes from baseline to treatment end for metacognitive capacity measured by the Metacognition Assessment Scale-Abbreviated. Nine of twelve patients finished treatment. However, nonsignificant moderate to large effect sizes were obtained on the primary outcome measure. This study is among the first to suggest that patients with schizophrenia will accept metacognitive therapy and evidence improvements in metacognitive capacity. Despite limitations typical to a pilot study, including a small sample size and lack of a control group, sufficient evidence of efficacy was obtained to warrant further investigation